Pleiotropic effects of nifedipine on atherosclerosis

Sho Ichi Yamagishi, Kazuo Nakamura, Katsuhiko Takenaka, Takanori Matsui, Hiroyoshi Inoue

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatory-fibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.

Original languageEnglish
Pages (from-to)1543-1547
Number of pages5
JournalCurrent Pharmaceutical Design
Volume12
Issue number12
DOIs
Publication statusPublished - 2006 Apr
Externally publishedYes

Fingerprint

Nifedipine
Atherosclerosis
Inflammation
L-Type Calcium Channels
Blood Vessels
Intercellular Signaling Peptides and Proteins
Cardiovascular Diseases
Endothelial Cells
Cytokines
Hypertension
Calcium
Growth
Therapeutics

Keywords

  • Advanced glycation end products
  • Atherosclerosis
  • Diabetes
  • Insulin resistance
  • Nitric oxide
  • Oxidative stress

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pleiotropic effects of nifedipine on atherosclerosis. / Yamagishi, Sho Ichi; Nakamura, Kazuo; Takenaka, Katsuhiko; Matsui, Takanori; Inoue, Hiroyoshi.

In: Current Pharmaceutical Design, Vol. 12, No. 12, 04.2006, p. 1543-1547.

Research output: Contribution to journalArticle

Yamagishi, SI, Nakamura, K, Takenaka, K, Matsui, T & Inoue, H 2006, 'Pleiotropic effects of nifedipine on atherosclerosis', Current Pharmaceutical Design, vol. 12, no. 12, pp. 1543-1547. https://doi.org/10.2174/138161206776389877
Yamagishi, Sho Ichi ; Nakamura, Kazuo ; Takenaka, Katsuhiko ; Matsui, Takanori ; Inoue, Hiroyoshi. / Pleiotropic effects of nifedipine on atherosclerosis. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 12. pp. 1543-1547.
@article{c8a91a15bc324a0c824e1316c9733827,
title = "Pleiotropic effects of nifedipine on atherosclerosis",
abstract = "Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatory-fibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.",
keywords = "Advanced glycation end products, Atherosclerosis, Diabetes, Insulin resistance, Nitric oxide, Oxidative stress",
author = "Yamagishi, {Sho Ichi} and Kazuo Nakamura and Katsuhiko Takenaka and Takanori Matsui and Hiroyoshi Inoue",
year = "2006",
month = "4",
doi = "10.2174/138161206776389877",
language = "English",
volume = "12",
pages = "1543--1547",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Pleiotropic effects of nifedipine on atherosclerosis

AU - Yamagishi, Sho Ichi

AU - Nakamura, Kazuo

AU - Takenaka, Katsuhiko

AU - Matsui, Takanori

AU - Inoue, Hiroyoshi

PY - 2006/4

Y1 - 2006/4

N2 - Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatory-fibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.

AB - Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatory-fibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.

KW - Advanced glycation end products

KW - Atherosclerosis

KW - Diabetes

KW - Insulin resistance

KW - Nitric oxide

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=33745084325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745084325&partnerID=8YFLogxK

U2 - 10.2174/138161206776389877

DO - 10.2174/138161206776389877

M3 - Article

VL - 12

SP - 1543

EP - 1547

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 12

ER -